This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Impax Labs, Subaye: After-Hours Trading

Stocks in this article: IPXL SBAY HPQ TXN ZAGG

NEW YORK ( TheStreet) -- Shares of Impax Laboratories (IPXL - Get Report) surged in late trades on Monday after the company reported positive results for a late-stage trial of a proposed treatment for advanced Parkinson's disease.

The company's phase III trial of the safety and efficacy of its IPX066 drug versus immediate-release carbidopa-levodopa IR CD-LD "produced significantly improved control of motor symptoms as compared to IR CD-LD in multiple clinical measures in subjects with advanced PD Parkinson's disease ."

The stock was last quoted at $24.74, up 12.1%, on volume of roughly 40,000, according to

The company said the primary endpoint of the study was focused on a percentage of "off time" -- defined by Impax as the "functional state when patients' medication effect has worn off and there is a return of Parkinson's symptoms" -- and IPXO66 demonstrated a 37% improvement from baseline vs. a 17% improvement for IR CD-LD.


Chinese media and entertainment services provider Subaye (SBAY) plunged in late trades on Monday after the company announced the resignation of its chief financial officer.

In a Form 8-K filing with the Securities and Exchange Commission, Subaye said James Crane, who has served as its CFO since October 2007, disclosed his plans to resign to pursue other professional interests on March 10. The company named Alan Lun, its president and a director, is assuming the CFO post.

The stock was down almost 36% to $3.80 on volume of a little less than 30,000 in extended trades.


Shares of Zagg (ZAGG - Get Report) were weak after Monday's closing bell as the Salt Lake City-based maker of covers and other accessories for smart phones and tablets reported its fourth-quarter results, edging Wall Street's profit estimate by a penny.

The company said it earned $3.4 million, or 13 cents a share, in the three months ended Dec. 31 on revenue of $29.3 million, up 27% from its third-quarter total. The average estimate of five analysts polled by Thomson Reuters was for earnings of 12 cents a share on revenue of $21.2 million.

The shares settled in the extended session at $7.80, down 3.8%, on volume of more than 400,000. The stock bounced however off an after-hours low of $6.55 as the company's decision to delay its conference call by an hour caused some consternation among investors.

In addition, Zagg announced the resignation of Lorance Harmer from its board after the bell while naming Cheryl Larabee as a director. Harmer was a director with the company dating back to May 2008, and had also served as the chairman of Zagg's audit committee.

Zagg's best known product is its invisiSHIELD, and the stock sold off earlier in March when Apple (AAPL) unveiled its own protective cover product for the second-generation of the iPad 2.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,672.60 -141.38 -0.79%
S&P 500 2,051.82 -11.33 -0.55%
NASDAQ 4,757.8790 +7.4820 0.16%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs